Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

Journal of Neuroimmunology

Volumn 99, Issue 1, 1999, Pages 142-149

  Gobbini, Maria Ida ^a   Smith, Mary E ^a   Richert, Nancy D ^b   Frank, Joseph A ^b   McFarland, Henry F ^a  

^a Natl Insitutes Hlth Bldg 10 R   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cyclophosphamide; Gadolinium; Magnetic resonance; Multiple sclerosis; White matter lesion load

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GADOLINIUM; METHYLPREDNISOLONE; ONDANSETRON; PREDNISONE; TRIMETHOBENZAMIDE;

ADULT; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT OUTCOME;

ADULT; AUTOIMMUNE DISEASES; BRAIN; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0032879010     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00039-9     Document Type: Article

References (36)

1. Boumpas D.T., Austin J.H., Vaughan E.M.et al. Risk for sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Int. Med. 119:1993;366-369.
2. Canadian Cooperative Multiple Sclerosis Study Group The Canadian cooperative trial of cyclophosphamide and plasmaexchange in progressive multiple sclerosis. Lancet. 337:1991;441-446.
3. Chabner, B.A., Allegra, C.J., Curt, G.A., et al., 1996. Antineoplastic agents, In: Goodman, Gilman (Eds.), The Pharmacological Basis of Thrapeutics, Chapter 51, 9th edition, Mcgraw-Hill.
4. D'Andrea F., D'Aurizio C., Marini C. et al. Cyclophosphamide in relapsing remitting multiple sclerosis. Ital. J. Neurol. Sci. 11:1990;271-274.
5. De Carli, C., Stone, L.A., Frank, J.A., et al. A semiautomated statistical method for quantifying white matter lesions on MRI in patients with multiple sclerosis, Mult Scler, in press.
6. Drachman D.A., Paterson P.Y., Schmidt R.T.et al. Cyclophosphamide. J. Neurol. 214:1977;173-181.
7. Edan G., Miller D., Clanet M.et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry. 62:1997;112-118.
8. Goodkin D.E., Plencner S., Palmer-Saxerud J.et al. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs. non-maintenance therapy. Arch. Neurol. 44:1987;823-827.
9. Hafler D.A., Weiner H.L. Immunologic mechanism and therapy in multiple sclerosis. Immunol. Rev. 144:1995;75-107.
10. Harris J.O., Frank J.A., Patronas N.et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann. Neurol. 29:1991;548-555.
11. Hauser S.L., Dawson D.M., Lehrich J.R.et al. Intensive immunosuppression in progressive multiple sclerosis. New Engl. J. Med. 308:1983;173-180.
12. Hoffman G.S., Leavitt R.Y., Fleisher T.A.et al. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am. J. Med. 89:1990;403-411.
13. Hohol M.J., Olek M.J., Orav J.et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to duration of progressive disease. Nurology. 50:1998;A146. Suppl. 4.
14. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
15. Killian J.M., Bressler R.B., Armstrong R.M.et al. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch. Neurol. 45:1988;27-30.
16. Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic disease. Semin. Arthritis Rheum. 12:1983;359-372.
17. Likosky W.H., Fireman B., Elmore R.et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J. Neurol. Neurosurg. Psychiatry. 54:1991;1055-1060.
18. Martin F., Lauwerys B., Lefebre C.et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus. 6:1997;254-257.
19. Martindale. The Extra Pharmacopoeia, 31st edition, Royal Pharmaceutical Society, London, 1996, pp. 554-557.
20. McFarland H.F., Frank J.A., Albert P.S.et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 32:1992;758-766.
21. Merkel F., Netzer K.O., Gross O.et al. Therapeutic options for critically ill patients suffering from progressive lupus nephritis or Goodpasture's syndrome. Kidney International. 53:1998;S31-S38. Suppl 64.
22. Millac P., Miller H. Cyclophosphamide in multiple sclerosis. Lancet. 1:1969;783. (letter).
23. Millefiorini E., Di Giovanni M., Bernardi S.et al. Twenty-four-month follow-up of multiple sclerosis patients treated with cyclophosphamide. Ital. J. Neurol. Sci. 11:1990;605-607.
24. Miller D.H. Magnetic resonance in monitoring the treatemnt of multiple sclerosis. Ann. Neurol. 36:1994;S91-S94. Suppl.
25. Miller D.H., Grossman R.I., Reingold S.C.et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 121:1998;3-24.
26. Moreau T., Thorpe J., Miller D.et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 344(8918):1994;298-301.
27. Paterson P., Drobish D.G. Cyclophosphamide: Effect on Experimental Allergic Encephalomyelitis in Lewis Rats. Science. 165:1969;191-192.
28. Richmond R., McMillan T.W., Luqmani R.A. Optimisation of cyclophosphamide therapy in systemic vasculitis. Clin. Pharmacokinet. 34(1):1998;79-90.
29. Schroeder J., Euler H.H. Recognition and management of Systemic Lupus Erythematosus. Drug. 54(3):1997;422-434.
30. Sipe J.C., Romine J.S., Koziol J.A.et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 344(8914):1994;9-13.
31. Stone L.A., Frank J.A., Albert P.S.et al. Characterization of MRI response to treatment with interferon beta 1-b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology. 49(3):1995;862-869.
32. Stone L.A., Frank J.A., Albert P.S.et al. The effect of Interferon-beta on blood-brain barrier disruptions demonstreted by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37:1995;611-619.
33. Stone, L.A., Frank, J.A., McFarland, H.F., Private communication.
34. Unger C., Eibl H., von Heyden H.W. Blut-Hirnschranke und Penetration von Zytostatika. Klin. Wochenschr. 63:1985;565-571.
35. Weiner H.L., Mackin G.A., Orav E.J.et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 43(5):1993;910-918.
36. Weinstock-Guttman B., Kinkel R.P., Cohen J.A.et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist. 3:1997;178-185.